1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDeveloping Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants Use Disorders (OUD/StUD) R43/44 SBIR is sponsored by National Institute on Drug Abuse (NIDA). This program supports small businesses in developing regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulant use disorders.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) | Research Funding National Institutes of Health Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD).
Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device.
This FOA strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis.
Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply. Letter of Intent Due Date(s): 30 days prior to receipt date Application Due Dates: Aug.
15, 2022; Feb 14, 2023; Aug 15, 2023; Feb 14, 2024; Aug 13, 2024; Feb 14, 2025 RFA-DA-23-021 Expiration Date February 15, 2025 Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. Total funding support (direct costs, indirect costs, fee) may not exceed $320,000 for Phase I awards and $2,500,000 for Phase II awards. Engineering and Physical Sciences Medical - Clinical Science
According to the current listing, eligibility includes: Small businesses. Confirm the full requirements in the official notice before applying.
The current listing shows up to $400,000 for Phase I; up to $3,000,000 for Phase II. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants Use Disorders (OUD/StUD) R43/44 SBIR is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article